The Buying Group Paid by the Companies It Negotiates Against
Hospitals purchase most supplies through organisations that aggregate demand and negotiate contracts. Those organisations are funded by fees paid by the suppliers whose prices they are meant to be driving down.
Aggregating Demand Is Genuinely Useful
A single hospital buying gloves, sutures, implants, and imaging equipment negotiates alone against manufacturers far larger than it is. A thousand hospitals buying together have leverage.
Group purchasing organisations exist to provide that aggregation. They negotiate contracts with suppliers on behalf of member hospitals, who can then buy at the negotiated terms without conducting their own negotiations.
The value is real. Members avoid the cost of negotiating thousands of contracts, obtain prices reflecting collective volume, and receive contracting expertise a small hospital could not employ. Estimates of the share of hospital supply spend flowing through these arrangements run above two thirds.
Who Pays for It
The funding model is the point of contention and it is unusual enough to state plainly.
These organisations are funded primarily by administrative fees paid by the suppliers whose contracts they award, typically calculated as a percentage of the value of products sold through the contract. A portion is generally shared back with member hospitals.
So the organisation negotiating prices down is compensated as a percentage of the amount its members spend, by the party selling to them.
| Party | Pays | Receives |
|---|---|---|
| Member hospital | Small or no membership fee | Negotiated prices, fee share |
| Supplier | Administrative fee on sales | Access to member volume |
| Purchasing organisation | Operating costs | Fee revenue scaling with spend |
An organisation paid a percentage of what its members spend has a revenue interest in higher prices and higher volumes. That is not an allegation about any particular contract, it is a description of the incentive that the funding model creates.
The Legal Foundation
The arrangement would ordinarily raise serious questions under healthcare anti kickback law, which prohibits remuneration in exchange for referrals or purchases of items reimbursed by federal healthcare programmes.
A payment from a supplier to an entity that steers purchasing toward that supplier is precisely what the statute addresses. The practice exists because legislation in 1986 created a statutory exception, and regulations established a safe harbour for group purchasing arrangements meeting specified conditions, including a written agreement, disclosure of the fees to members, and either a fee at or below three percent or full disclosure of the amount.
The industry as it exists is therefore a creation of a specific legislative choice, not an outcome the general law would have permitted.
The Criticisms
Three arguments recur and each has some evidentiary basis.
Innovation foreclosure. A small manufacturer with a better product must obtain a contract to reach hospitals, and contracts are frequently long term, sole source, or bundled across product categories. Bundling in particular, where favourable pricing on one category is conditioned on purchasing others, can make it impossible for a single product entrant to compete on the merits. Senate investigations in the early 2000s examined exactly this and produced industry code of conduct commitments.
Concentration. A small number of organisations account for the large majority of hospital purchasing, which means a supplier excluded from those contracts is effectively excluded from the market.
Supply chain fragility. Contracts awarded on price to a small number of suppliers concentrate production, and shortages of generic injectable drugs and basic supplies have been attributed in part to purchasing practices that drove margins so low that manufacturers exited or under invested in capacity. When a single plant produces most of the national supply of a saline solution or a common generic, a single disruption becomes a national shortage.
The Defence
The industry response is substantive and worth stating.
Members choose to participate and can contract directly whenever they prefer, and many do for high value physician preference items such as implants. Fee disclosure is required. And independent analyses have found meaningful savings relative to what individual hospitals would achieve alone.
The counter to the incentive argument is that members would leave if prices were not competitive, and that competition among purchasing organisations disciplines the outcome.
That defence is stronger for commodity supplies, where prices are comparable and members can verify performance, and weaker for categories where price transparency is poor.
What Changed Recently
Shortages during and after the pandemic drew renewed attention, and several developments followed.
Some large health systems formed their own purchasing entities or invested directly in manufacturing capacity, most notably a not for profit generic drug manufacturer created by a group of hospital systems specifically to address shortage prone products. That is an explicit judgement that the existing purchasing model was not producing supply reliability.
Contracting practice has also shifted toward including supply assurance commitments and dual sourcing requirements rather than awarding purely on price, which addresses the fragility criticism directly by accepting a higher price for resilience.
The Bottom Line
Group purchasing delivers genuine savings by aggregating demand that would otherwise be fragmented across thousands of hospitals, and it is funded by the suppliers it negotiates against under a specific statutory exception without which it would be unlawful. The conflict is structural rather than hypothetical, and the strongest evidence of its cost is not in prices but in supply reliability, where relentless price competition on commodity products concentrated production to the point where single failures became national shortages.